A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement
Tekijät: Petra Stute, Areti Spyropoulou, Vasilios Karageorgiou, Antonio Cano, Johannes Bitzer, Iuliana Ceausu, Peter Chedraui, Fatih Durmusoglu, Risto Erkkola, Dimitrios G. Goulis, Angelica Lindén Hirschberg, Ludwig Kiesel, Patrice Lopes, Amos Pines, Margaret Rees, Mick van Trotsenburg, Iannis Zervas, Irene Lambrinoudaki
Kustantaja: ELSEVIER IRELAND LTD
Julkaisuvuosi: 2020
Journal: Maturitas
Tietokannassa oleva lehden nimi: MATURITAS
Lehden akronyymi: MATURITAS
Vuosikerta: 131
Aloitussivu: 91
Lopetussivu: 101
Sivujen määrä: 11
ISSN: 0378-5122
eISSN: 1873-4111
DOI: https://doi.org/10.1016/j.maturitas.2019.11.002
Introduction: Globally, the total number of people with depression exceeds 300 million, and the incidence rate is 70 % greater in women. The perimenopause is considered to be a time of increased risk for the development of depressive symptoms and major depressive episodes.Aim: The aim of this position statement is to provide a comprehensive model of care for the management of depressive symptoms in perimenopausal and early menopausal women, including diagnosis, treatment and follow-up. The model integrates the care provided by all those involved in the management of mild or moderate depression in midlife women.Materials and methods: Literature review and consensus of expert opinion.Summary recommendations: Awareness of depressive symptoms, early detection, standardized diagnostic procedures, personalized treatment and a suitable follow-up schedule need to be integrated into healthcare systems worldwide. Recommended treatment comprises antidepressants, psychosocial therapies and lifestyle changes. Alternative and complementary therapies, although widely used, may help with depression, but a stronger evidence base is needed. Although not approved for this indication, menopausal hormone therapy may improve depressive symptoms in peri- but not in postmenopausal women, especially in those with vasomotor symptoms.
